JAK2 and acquired polycythemia vera: Ruxolitinib is a tyrosine kinase inhibitor inhibiting both JAK1 and JAK2, and was approved for the treatment of intermediate and high-risk MF and as second-line therapy for PV refractory to HU treatment.